ArticleFrontiers in pharmacology2020
Serum Metabolic Profiling Reveals the Antidepressive Effects of the Total Iridoids of
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Analysis of gut microbiota and intestinal mucosal neurotransmitter changes and their correlation in adolescent depression mice.Annals of general psychiatry · 2026Article
- Prenatal psychological stress mediates vertical transmission of gut microbiome to the next generation affecting offspring depressive-like behaviors and neurotransmitter.BMC psychology · 2025Article
- Iridoids derived from Valeriana jatamansi Jones alleviates neuroinflammation and blood spinal cord barrier permeability after spinal cord injury by activating the Nrf2/HO-1 signaling pathway.Frontiers in pharmacology · 2025Article
- Lower creatinine levels are associated with an increased risk of depression: evidence from the China Health and Retirement Longitudinal Study.Frontiers in psychiatry · 2025Article
- Serum Metabolites as Potential Markers and Predictors of Depression-like Behavior and Effective Fluoxetine Treatment in Chronically Socially Isolated Rats.Metabolites · 2024Article
- Effects of Xiaoyao San on exercise capacity and liver mitochondrial metabolomics in rat depression model.Chinese herbal medicines · 2024Article
- Circulating metabolites and depression: a bidirectional Mendelian randomization.Frontiers in neuroscience · 2023Article
- Therapeutic potential of plant iridoids in depression: a review.Pharmaceutical biology · 2022Review
- Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.European archives of psychiatry and clinical neuroscience · 2022Article
- The potential ofFrontiers in pharmacology · 2022Review
- Spectrum-Efficacy Relationships between GC-MS Fingerprints of Essential Oil from Valerianae Jatamansi Rhizoma et Radix and the Efficacy of Inhibiting Microglial Activation.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Antidepressant effects of total iridoids ofPharmaceutical biology · 2021Article
- Plant Species of Sub-Family Valerianaceae-A Review on Its Effect on the Central Nervous System.Plants (Basel, Switzerland) · 2021Review
- Safety of high-doseFood science & nutrition · 2021Article
- The Combination ofFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is a long-term complex psychiatric disorder, and its etiology remains largely unknown.
methodsHere, CUMS was used to establish a mouse model of depression. Behavioral and biochemical indicators were investigated to evaluate the pharmacodynamic effects. A comprehensive serum metabolomics study by nuclear magnetic resonance (NMR) approach was applied to investigate the pharmacological mechanism of IRFV in CUMS mouse. Subsequently, we used multivariate statistical analysis to identify metabolic markers, such as principal component analysis (PCA) and orthogonal projection to latent structure with discriminant analysis (OPLS-DA), to distinguish between the CUMS mouse and the control group.
resultsAfter IRFV treatment, the immobility time, sucrose preference, and monoamine neurotransmitter were improved. PCA scores showed clear differences in metabolism between the CUMS group and control group. The PLS-DA or OPLS-DA model exhibited 26 metabolites as biomarkers to distinguish between the CUMS mice and the control mouse. Moreover, IRFV could significantly return 21 metabolites to normal levels.
conclusionThe results confirmed that IRFV exerted an antidepressive effect by regulating multiple metabolic pathways, including the tricarboxylic acid cycle, the synthesis of neurotransmitters, and amino acid metabolism. These findings provide insights into the antidepressive mechanisms of IRFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.